Arc Institute scientists introduced a universal gene editing platform leveraging bridge recombinases to enable precise, megabase-scale DNA rearrangements in human cells. This technology facilitates cutting, pasting, insertion, deletion, and inversion of extensive genomic regions, surpassing previous limitations of small edits. The approach promises transformative therapeutic potential by enabling scalable genetic engineering applicable to complex diseases. High insertion efficiencies of up to 20% have been demonstrated, marking a paradigm shift in genome editing capabilities.